上海药明生物技术有限公司 Wuxi Biologics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
WuXi Biologics Reports Solid 2023 Annual Results 2024-03-26 21:53
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment 2024-03-05 21:00
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics 2024-02-21 18:00
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland 2024-01-31 17:31
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect 2024-01-25 08:30
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ 2024-01-17 08:30
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts 2024-01-08 17:52
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index 2023-12-12 17:00
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating 2023-12-08 17:40
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale 2023-11-22 13:21
WuXi Biologics Receives AAA MSCI ESG Rating 2023-11-08 08:30
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality 2023-10-17 08:30
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease 2023-10-02 08:30
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services 2023-08-11 08:30
WuXi Biologics to Increase Manufacturing Capacity in Germany 2023-06-01 16:49
WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations 2023-05-22 16:30
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients 2023-05-16 16:00
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability 2023-04-28 14:43
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease 2023-03-28 20:11
WuXi Biologics Reports Remarkable 2022 Annual Results 2023-03-22 20:09
1 2 3 4 5 8